AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
AGC Biologics Expands pDNA and mRNA Manufacturing Capacity
Nick McDonald on 9/13/21 5:00 PM News
Learn More
AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site
Matteo Pellegrino on 8/20/21 10:30 AM News
(COPENHAGEN), August 20, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site. This multipurpose facility will allow AGC Biologics to increase its capacity and space to accommodate new and existing clients’ needs.
AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site
Matteo Pellegrino on 8/9/21 10:00 PM News
(LONGMONT), August 9, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new leadership appointment to oversee strategic development and operational excellence in large-scale C> production at its Longmont site in Colorado. Effective August 9, 2021, Tony Fraij will join the Longmont team as General Manager/Site Head.
AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings
Matteo Pellegrino on 8/5/21 9:00 AM News
AGC Biologics acquires Longmont, Colorado facility to expand its global footprint and increase its C> process development and GMP capacity
(SEATTLE), August 5, 2021 – AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the finalization of the purchase of a state-of-the-art commercial manufacturing facility in Longmont, Colorado, USA. The facility, previously owned by Novartis Gene Therapies, will provide AGC Biologics with significant additional capacity and space to continue to expand its global end-to-end Cell and Gene Therapy (C>) offering, ensuring security of supply for current and future C> customers.
AGC Biologics Appoints Kevin Ingham as the new General Manager/Site Head of their Seattle, Washington Site
Matteo Pellegrino on 8/2/21 11:00 AM News
(SEATTLE), August 2, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the strategic development and operational excellence in clinical and commercial biologics production at its Seattle, Washington site. Effective August 2, 2021, Kevin Ingham will join the Seattle team as the General Manager/Site Head.
AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings
Matteo Pellegrino on 7/1/21 9:00 AM News
(SEATTLE), July 1, 2021 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, currently owned by Novartis Gene Therapies. Once the transaction closes, pending final due diligence, the facility will equip AGC Biologics with significant additional capacity and space to continue to expand its end-to-end Cell and Gene Therapy (C>) offering, ensuring security of supply for current and future C> customers. This facility is only 16 miles from AGC Biologics’ state-of-the-art large-scale stainless steel mammalian facility in Boulder, CO.
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
Matteo Pellegrino on 6/23/21 5:30 AM News
TEL AVIV, Israel and SEATTLE, Wash. June 21, 2021 – Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness.
AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
David Self on 6/7/21 7:00 AM News
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.
AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics
David Self on 5/19/21 10:06 AM News
(SEATTLE), May 19, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others. This award is dedicated to showcasing the best of the Italian M&A market.
(SEATTLE), May 6, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.
Follow Us
